Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT05064150
What this trial is testing

Neuroendocrine Tumors - Patient Reported Outcomes

Who this might be right for
Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm+1 more
University of Iowa 2,539
Large-scale testing (Phase 3)Looking for participantsNCT06784752
What this trial is testing

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Who this might be right for
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals 240
Not applicableStudy completedNCT00745381
What this trial is testing

A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors

Who this might be right for
Gastric CancerPancreatic Cancer
Memorial Sloan Kettering Cancer Center 238
Not applicableWithdrawnNCT03895463
What this trial is testing

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

Who this might be right for
Neuroendocrine Tumors
Ipsen
Not applicableStudy completedNCT04649580
What this trial is testing

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

Who this might be right for
Neuroendocrine Tumours (NET)
Ipsen 80
Not applicableStudy completedNCT04727723
What this trial is testing

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 164
Not applicableStudy completedNCT04986085
What this trial is testing

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 399
Post-approval studies (Phase 4)Looking for participantsNCT05701241
What this trial is testing

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Antwerp 270
Very early researchActive Not RecruitingNCT04544098
What this trial is testing

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Who this might be right for
Neuroendocrine TumorsLiver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center 10
Early research (Phase 1)Not Yet RecruitingNCT07661420
What this trial is testing

211At-MABG in Adults With Advanced Neuroendocrine Cancers

Who this might be right for
PheochromocytomaParagangliomaNeuroendocrine Tumors+3 more
University of Pennsylvania 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135
What this trial is testing

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Advanced Accelerator Applications 11
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Large-scale testing (Phase 3)Study completedNCT00690430
What this trial is testing

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Who this might be right for
Symptomatic Refractory Resistant Carcinoid Disease
Novartis Pharmaceuticals 186
Large-scale testing (Phase 3)Study completedNCT01842165
What this trial is testing

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Jules Bordet Institute 37
Testing effectiveness (Phase 2)Study completedNCT03220217
What this trial is testing

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Who this might be right for
Gastro-Enteropancreatic Neuroendocrine Tumor
Ipsen 29
Testing effectiveness (Phase 2)UnknownNCT04427787
What this trial is testing

A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Who this might be right for
Metastatic Well Differentiated Neuroendocrine NeoplasmNeuroendocrine Tumors
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 69
Large-scale testing (Phase 3)Ended earlyNCT01755182
What this trial is testing

Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
National Cancer Institute, Naples 1
Very early researchUnknownNCT05359146
What this trial is testing

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Not applicableStudy completedNCT02948946
What this trial is testing

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm
H. Lee Moffitt Cancer Center and Research Institute 105
Next Page